Literature DB >> 23260230

Chronic antidepressant treatment impairs the acquisition of fear extinction.

Nesha S Burghardt1, Torfi Sigurdsson, Jack M Gorman, Bruce S McEwen, Joseph E LeDoux.   

Abstract

BACKGROUND: Like fear conditioning, the acquisition phase of extinction involves new learning that is mediated by the amygdala. During extinction training, the conditioned stimulus is repeatedly presented in the absence of the unconditioned stimulus, and the expression of previously learned fear gradually becomes suppressed. Our previous study revealed that chronic treatment with a selective serotonin reuptake inhibitor (SSRI) impairs the acquisition of auditory fear conditioning. To gain further insight into how SSRIs affect fear learning, we tested the effects of chronic SSRI treatment on the acquisition of extinction.
METHODS: Rats were treated chronically (22 days) or subchronically (9 days) with the SSRI citalopram (10 mg/kg/day) before extinction training. The results were compared with those after chronic and subchronic treatment with tianeptine (10 mg/kg/day), an antidepressant with a different method of action. The expression of the NR2B subunit of the N-methyl-D-aspartate receptor in the amygdala was examined after behavioral testing.
RESULTS: Chronic but not subchronic administration of citalopram impaired the acquisition of extinction and downregulated the NR2B subunit of the N-methyl-D-aspartate receptor in the lateral and basal nuclei of the amygdala. Similar behavioral and molecular changes were found with tianeptine treatment.
CONCLUSIONS: These results provide further evidence that chronic antidepressant treatment can impair amygdala-dependent learning. Our findings are consistent with a role for glutamatergic neurotransmission in the final common pathway of antidepressant treatment.
Copyright © 2013 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23260230      PMCID: PMC3610782          DOI: 10.1016/j.biopsych.2012.10.012

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  101 in total

1.  Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning.

Authors:  R G Phillips; J E LeDoux
Journal:  Behav Neurosci       Date:  1992-04       Impact factor: 1.912

2.  Switching on and off fear by distinct neuronal circuits.

Authors:  Cyril Herry; Stephane Ciocchi; Verena Senn; Lynda Demmou; Christian Müller; Andreas Lüthi
Journal:  Nature       Date:  2008-07-09       Impact factor: 49.962

Review 3.  Tianeptine: a review of its use in depressive disorders.

Authors:  A J Wagstaff; D Ormrod; C M Spencer
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid.

Authors:  G Nowak; R Trullas; R T Layer; P Skolnick; I A Paul
Journal:  J Pharmacol Exp Ther       Date:  1993-06       Impact factor: 4.030

Review 5.  Pharmacological treatment of generalized anxiety disorder.

Authors:  David S Baldwin; Khalil I Ajel; Matthew Garner
Journal:  Curr Top Behav Neurosci       Date:  2010

6.  Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats.

Authors:  David L Walker; Kerry J Ressler; Kwok-Tung Lu; Michael Davis
Journal:  J Neurosci       Date:  2002-03-15       Impact factor: 6.167

7.  Expression of estrogen receptors (alpha, beta) and androgen receptor in serotonin neurons of the rat and mouse dorsal raphe nuclei; sex and species differences.

Authors:  Zijing Sheng; June Kawano; Akie Yanai; Ryutaro Fujinaga; Mayumi Tanaka; Yoshifumi Watanabe; Koh Shinoda
Journal:  Neurosci Res       Date:  2004-06       Impact factor: 3.304

8.  Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia.

Authors:  Jonathan R T Davidson; Edna B Foa; Jonathan D Huppert; Francis J Keefe; Martin E Franklin; Jill S Compton; Ning Zhao; Kathryn M Connor; Thomas R Lynch; Kishore M Gadde
Journal:  Arch Gen Psychiatry       Date:  2004-10

9.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

10.  Serotonin 5-HT1A receptors regulate NMDA receptor channels through a microtubule-dependent mechanism.

Authors:  Eunice Y Yuen; Qian Jiang; Paul Chen; Zhenglin Gu; Jian Feng; Zhen Yan
Journal:  J Neurosci       Date:  2005-06-08       Impact factor: 6.709

View more
  30 in total

Review 1.  Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions.

Authors:  Michael W Otto; M Alexandra Kredlow; Jasper A J Smits; Stefan G Hofmann; David F Tolin; Rianne A de Kleine; Agnes van Minnen; A Eden Evins; Mark H Pollack
Journal:  Biol Psychiatry       Date:  2015-09-25       Impact factor: 13.382

2.  Side-effects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial.

Authors:  Adam M Reid; Joseph P H McNamara; Tanya K Murphy; Andrew G Guzick; Eric A Storch; Wayne K Goodman; Gary R Geffken; Regina Bussing
Journal:  J Psychiatr Res       Date:  2015-10-14       Impact factor: 4.791

3.  Sex differences and estrous cycle in female rats interact with the effects of fluoxetine treatment on fear extinction.

Authors:  K Lebrón-Milad; A Tsareva; N Ahmed; M R Milad
Journal:  Behav Brain Res       Date:  2013-07-22       Impact factor: 3.332

4.  Acute tianeptine treatment selectively modulates neuronal activation in the central nucleus of the amygdala and attenuates fear extinction.

Authors:  B P Godsil; B Bontempi; F Mailliet; P Delagrange; M Spedding; T M Jay
Journal:  Mol Psychiatry       Date:  2015-01-06       Impact factor: 15.992

5.  De novo fear conditioning across diagnostic groups in the affective disorders: evidence for learning impairments.

Authors:  Michael W Otto; Samantha J Moshier; Dina G Kinner; Naomi M Simon; Mark H Pollack; Scott P Orr
Journal:  Behav Ther       Date:  2014-01-05

Review 6.  Mechanisms to medicines: elucidating neural and molecular substrates of fear extinction to identify novel treatments for anxiety disorders.

Authors:  Olena Bukalo; Courtney R Pinard; Andrew Holmes
Journal:  Br J Pharmacol       Date:  2014-07-23       Impact factor: 8.739

Review 7.  Sex differences in fear extinction.

Authors:  E R Velasco; A Florido; M R Milad; R Andero
Journal:  Neurosci Biobehav Rev       Date:  2019-05-23       Impact factor: 8.989

Review 8.  From Pavlov to PTSD: the extinction of conditioned fear in rodents, humans, and anxiety disorders.

Authors:  Michael B VanElzakker; M Kathryn Dahlgren; F Caroline Davis; Stacey Dubois; Lisa M Shin
Journal:  Neurobiol Learn Mem       Date:  2013-12-07       Impact factor: 2.877

9.  Overlapping expression of serotonin transporters and neurokinin-1 receptors in posttraumatic stress disorder: a multi-tracer PET study.

Authors:  A Frick; F Åhs; Å M Palmquist; A Pissiota; U Wallenquist; M Fernandez; M Jonasson; L Appel; Ö Frans; M Lubberink; T Furmark; L von Knorring; M Fredrikson
Journal:  Mol Psychiatry       Date:  2015-12-01       Impact factor: 15.992

10.  Escitalopram reversed the traumatic stress-induced depressed and anxiety-like symptoms but not the deficits of fear memory.

Authors:  Chen-Cheng Lin; Che-Se Tung; Yia-Ping Liu
Journal:  Psychopharmacology (Berl)       Date:  2016-01-07       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.